<DOC>
	<DOCNO>NCT01254409</DOCNO>
	<brief_summary>The aim study assess safety , tolerability , pharmacokinetic profile , pharmacodynamic profile multiple dose PRM-151 administer IV IPF patient .</brief_summary>
	<brief_title>A Phase 1b Study IV PRM151 Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>Idiopathic pulmonary fibrosis ( IPF ) diffuse lung disease histological picture usual interstitial pneumonia deteriorate clinical course . The prognosis poor . Chronic alveolar inflammation associate parenchymal remodel theorized promote ongoing abnormal fibrogenic repair response . Corticosteroids immunomodulatory agent show benefit IPF patient . Recently several publish clinical study indicate strong correlation IPF severity and/or disease progression level specific plasma biomarker protein relate epithelial cell health extracellular matrix turnover . PRM-151 develop potential therapeutic us prevent , treat , reduce fibrosis . This study first intravenous multiple-dose study human , conduct patient IPF . Patients randomize receive either PRM-151 placebo .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Men woman nonchildbearing potential age 40 80 year screen . Diagnosis idiopathic pulmonary fibrosis ( IPF ) determine high resolution computerize tomography ( HRCT ) pulmonary function test . History presence connective tissue disorder , tuberculosis ( TB ) , cystic fibrosis , sarcoidosis , amyloidosis pulmonary disease except idiopathic pulmonary fibrosis ( IPF ) . History presence chronic pulmonary obstructive disease , severe pulmonary hypertension , druginduced pulmonary toxicity , form idiopathic pneumonia , interstitial lung disease associate environmental exposure medication systemic disease . High resolution computerize tomography ( HRCT ) finding inconsistent idiopathic pulmonary fibrosis ( IPF ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pulmonary , fibrosis</keyword>
</DOC>